Related Experiment Video
Updated: Jan 9, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
Enzymatically Switchable Pyroptosis-Inducing Polymer Conjugate to Coordinate Host Immune Responses in Cancer
Torsha Ghosh1, Jueun Jeon1, Van Hieu Duong1
1School of Chemical Engineering, College of Engineering, Sungkyunkwan University, Suwon, 16419, Republic of Korea.
Abstract:
Gasdermin-D-mediated pyroptosis, an immunogenic cell death predominantly occurring in antigen-presenting cells, is pivotal in orchestrating innate and adaptive immunity. Therefore, this dynamic process holds significant potential as an effective cancer immunotherapy strategy. However, its adequate spatiotemporal control in cancer remains challenging. An Enzymatically switchable Pyroptosis-Inducing polymer Conjugate (EPIC) is reported that selectively triggers chemiluminescence resonance energy transfer (CRET) in the lysosome in the presence of Cathepsin B, abundant in cancer cells. When exposed to cancer cells in vitro, EPIC generates reactive oxygen species via self-immolation-mediated CRET, triggering lysosomal membrane disintegration, followed by activation of the signaling cascade that cleaves gasdermin-D. Cleaved gasdermin-D forms pyroptotic pores in the cancer cell membrane, promoting the efflux of damage-associated molecular patterns and inflammatory cytokines. When systemically administered into the tumor-bearing mice, EPIC provokes a robust immune response by promoting dendritic cell maturation and reinvigorating cytotoxic NK cells. Combination of EPIC with anti-PD-1 antibody enhanced infiltration of tumor-specific cytotoxic T cells and promoted memory T cells, resulting in a durable remission of established tumors with complete tumor regression in more than half of the treated mice. Overall, EPIC has potential as a nanoplatform with multifaceted advantages for precise and effective cancer immunotherapy.
Insights
A novel polymer conjugate, EPIC, precisely triggers pyroptosis (programmed cell death) in cancer cells. This approach enhances anti-tumor immunity and shows promise for effective cancer immunotherapy, leading to durable tumor remission.
Area of Science:
- Biomedical Engineering
- Immunology
- Oncology
Background:
- Gasdermin-D-mediated pyroptosis is crucial for immunity and a potential cancer immunotherapy target.
- Controlling pyroptosis spatiotemporally in cancer treatment remains a significant challenge.
Purpose of the Study:
- To develop a novel polymer conjugate (EPIC) for precise, enzyme-activated pyroptosis induction in cancer cells.
- To evaluate EPIC's efficacy as a cancer immunotherapy agent, alone and in combination with anti-PD-1 therapy.
Main Methods:
- An Enzymatically switchable Pyroptosis-Inducing polymer Conjugate (EPIC) was designed to activate via Cathepsin B in cancer cells.
- EPIC induces chemiluminescence resonance energy transfer (CRET) leading to reactive oxygen species generation and lysosomal disruption.
- In vitro and in vivo studies assessed EPIC's ability to trigger pyroptosis, activate immune cells, and treat tumors in mice.
Main Results:
- EPIC selectively triggered pyroptosis in cancer cells, releasing damage-associated molecular patterns and cytokines.
- In tumor-bearing mice, EPIC promoted dendritic cell maturation and NK cell activity.
- Combination therapy with EPIC and anti-PD-1 antibody significantly enhanced anti-tumor immunity, leading to durable remission and complete tumor regression in over 50% of mice.
Conclusions:
- EPIC serves as a versatile nanoplatform for precise cancer immunotherapy.
- EPIC demonstrates significant potential for effective cancer treatment by inducing immunogenic cell death and enhancing anti-tumor immune responses.
More Related Videos
Related Concept Videos
Tumor Immunotherapy
Targeted Cancer Therapies
There are several types of targeted therapies against...

